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ABSTRACT
The purpose of this study was to examine sex differences in oral-respiratory
mucosal immunity and the incidence, severity and duration of upper respiratory
symptoms (URS) episodes in endurance athletes during a 16-week winter training
period. Blood was collected from 210 subjects (147 men and 63 women) at the
start and end of the study for determination of differential leukocyte counts.
Timed collections of unstimulated saliva were obtained at the start and at 4-week
intervals during the study period. Saliva samples were analysed for salivary anti-
microbial peptides and proteins (AMPs). Weekly training and daily illness logs
were kept using validated questionnaires. Training loads averaged 11 h/week of
moderate-vigorous physical activity and were not different for males and females.
The salivary concentration of lysozyme and lactoferrin (both P<0.04) but not
salivary immunoglobulin A (SIgA) or amylase were higher in males than females.
Saliva flow rates were significantly higher in males than females (P < 0.03) and
consequently so were the salivary secretion rates of lysozyme, lactoferrin and
amylase (all P<0.01) but not SIgA (P = 0.097). Total blood leukocyte, monocyte
and lymphocyte counts were not different between the sexes but females had hig-
her numbers of circulating neutrophils (P = 0.040). The average number of URS
episodes was 0.6 ± 0.8 (mean ± SD) in males and 0.8 ± 1.0 in females (P = 0.103)
and the number of URS days was higher in females (4.7 vs 6.8 days, P < 0.02).
The duration of URS episodes was longer in females (11.6 vs 15.5 days, P <
0.03). The findings of this study concur with recent reports of illness incidence at
major competitive games indicating that female athletes may be more susceptible
than their male counterparts to URS and that lower oral-respiratory mucosal
immunity may, in part, account for this.
Keywords: exercise training, leukocytes, immunoglobulins, antimicrobial
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INTRODUCTION
Resistance to infection is strongly influenced by the effectiveness of the immune
system in protecting the host against pathogenic micro-organisms. Within the
general healthy human population there is a range of immuno-competency due to
genetic differences, age, nutritional deficiencies and lifestyle habits. The sex of
the individual also affects immune function. In females, oestrogens and proges-
terone modulate immune function (41) and thus immunity is influenced by the
menstrual cycle and pregnancy (29). Consequently, sex-based differences in
responses to infection, trauma and sepsis are evident (6). Within the general pop-
ulation women are generally more resistant to viral infections and tend to have
more autoimmune diseases than men (6). In a review of the literature on respira-
tory tract infections (RTIs) (20) in which data from 84 studies was extracted it
was concluded that males are more susceptible than females to most types of
RTIs in all age groups (children, adolescents, adults and the elderly). Anatomic,
lifestyle, behavioural and socioeconomic differences between males and females
may explain the observed findings and the involvement of sex hormones in the
regulation of immune function may also contribute to the reported sex differences
in the incidence and severity of the various types of RTIs, especially in adults and
adolescents (20). Oestrogens are generally immune enhancing, whereas andro-
gens, including testosterone, exert suppressive effects on both humoral and cellu-
lar immune responses. Females have higher levels of plasma immunoglobulin M
(IgM) than men and exhibit more vigorous responses to exogenous antigens, indi-
cating a higher level of humoral immunity in females than in males (8). In
females, there is increased expression of some cytokines in peripheral blood and
vaginal fluids during the follicular phase of the menstrual cycle and with use of
hormonal contraceptives (9). In the luteal phase of the menstrual cycle, blood
leukocyte counts are higher than in the follicular phase (18), mononuclear cell
expression of the heterodimeric transcription factor 1 (a key regulator of the
innate immune response) is lower (47), and the immune response is shifted
towards a T helper (Th) 2-type response (18). Thus, in the general population,
there are differences in some aspects of immune function between men and
women that appear to result in women getting fewer viral infections, including
those affecting the respiratory tract.
In addition to these sex differences in resting conditions, several studies have
documented sex differences in some aspects of the immunological response to
exercise (22, 49, 50) including larger post-exercise increases in circulating lym-
phocytes and natural killer cells in females. The expression of pro-inflammatory
and anti-inflammatory genes in response to exercise is also influenced by the
menstrual cycle and there are distinct differences in gene expression between
women in the luteal phase and men (40). Prolonged strenuous exercise has been
associated with a transient depression of immune function (23, 24, 53) and a
heavy schedule of training and competition can lead to immune impairment in
both male and female athletes (53). This is associated with an increased suscepti-
bility to upper respiratory symptoms (URS) (7, 19, 27, 30, 39, 43, 53) and several
studies suggest that reduced secretion of salivary immunoglobulin A (SIgA) and
possibly other mucosal antimicrobial proteins may be an important causal factor
(19, 24, 26, 27, 37, 53). However, it is not clear whether any substantial sex dif-
ferences exist in any aspect of oral-respiratory mucosal immune function in an
athletic population or whether any such differences affect URS risk. In contrast to
what has been reported for the general population, some recent reports of illness
rates among athletes attending large competitive events (e.g. winter and summer
Olympic games, athletic and aquatic sport world championships) suggest that
URS episodes may actually be more prevalent in the women than the men (4, 5,
14, 16, 17, 36, 46).
The aims of the present study were to determine if sex differences exist in resting
immune variables including saliva antimicrobial proteins (AMPs) including
SIgA, lysozyme, lactoferrin and amylase secretion and the numbers of circulating
leukocyte numbers in an athletic population. We also wished to determine if the
prevalence of URS episodes was different in male and female athletes during a
period of winter training and competition. Our hypothesis was that saliva AMP
secretion rates would be lower in females and that this might be associated with a
higher prevalence of URS episodes.
METHODS
Subjects
Two hundred and sixty seven subjects (83 females, 184 males) aged 21 ± 3 years
who were engaged in regular sports training (predominantly endurance-based
activities such as running, cycling, swimming, triathlon, team games and racquet
sports) from Loughborough University, UK volunteered to participate in the
study during November 2011. Since our study population was a group of univer-
sity athletes on a single campus site it is likely that environment and pathogen
exposure were similar for all subjects. Subjects ranged from recreationally active
to Olympic triathletes and their self-reported training loads (determined by a pre-
screening questionnaire) averaged 10 ± 3 h/week (mean ± SD). Two hundred and
ten subjects (63 females, 147 males) completed the study and provided sufficient
blood for routine haematology on 2 occasions and sufficient saliva for analysis of
AMPs on all 5 occasions. Their baseline characteristics as shown in Table 1.
Among the females 96% reported having regular periods and 40% were taking
oral contraceptives. Reasons for dropout were given as foreign travel, injury or
persistent non-respiratory illness (preventing subjects from performing training)
or due to undisclosed reasons.
Subjects were required to complete a comprehensive health-screening question-
naire prior to starting the study and had not taken any regular medication or
antibiotics in the 3 months prior to the study. All subjects were fully informed
about the rationale for the study and of all experimental procedures to be under-
taken. Subjects provided written consent to participate in the study, which had
earlier received the approval of Loughborough University ethical advisory com-
mittee. Subjects were enrolled after having fulfilled all inclusion criteria, and pre-
senting none of the exclusion criteria (determined by both questionnaire and
interview). Subjects could be included if they were currently healthy, had been
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involved in endurance training for at least 2 years, engaged in at least 3 sessions
and at least 3 h of total moderate/high-intensity training time per week and were
between 18-40 years of age. Subjects representing one or more of the following
criteria were excluded from participation: smoking or use of any medication, suf-
fering from or had a history of cardiac, hepatic, renal, pulmonary, neurological,
gastrointestinal, haematological or psychiatric illness.
Study protocol
For the first visit to the laboratory, subjects arrived in the morning at 08:30-10:30
following an overnight fast of approximately 12 h and no strenuous exercise in
the previous 24 h and their body mass and height were recorded. Information
about the study was given to them and they then signed an informed consent
form. Subjects then sat quietly for 10 min and completed a health-screening ques-
tionnaire and inclusion/exclusion criteria questionnaire before being asked to
swallow to empty their mouth of any residual saliva before providing an unstimu-
lated saliva sample by passive dribble into a pre-weighed sterile collection tube
for a timed period (usually 2 min; longer was allowed if the volume of saliva col-
lected after 2 min was insufficient). After centrifugation for 2 min at 5000 g to
remove cells and insoluble matter, saliva samples were stored frozen at -80ºC
prior to analysis. Subsequently, a resting venous blood sample (5 ml) was
obtained by venepuncture from an antecubital forearm vein into a vacutainer tube
(Becton Dickinson, Oxford, UK) containing K3EDTA for immediate haematolog-
ical analysis (including haemoglobin, haematocrit and total and differential
leukocyte counts) using an automated cell-counter (Ac.T™5diff haematology
analyser, Beckman Coulter, High Wycombe, UK). The intra-assay coefficient of
variation for all measured blood variables was less than 3.0%. Subjects had to
have all haematological values within the normal healthy range to be included in
the study.
During the 4-month study period subjects were requested to continue with their
normal training programs. Subjects completed a validated self-report health
(URS) questionnaire (29) on a daily basis. Subjects were not required to abstain
from medication when they were suffering from illness symptoms but they were
required, on a weekly basis, to report any unprescribed medications taken, visits
to the doctor or any prescribed medications. The illness symptoms listed on the
questionnaire were: sneezing, headache, malaise, nasal discharge, nasal obstruc-
tion, sore throat, cough, ear ache, hoarseness, fever, chilliness and joint aches and
pains. The non-numerical severity ratings of mild, moderate and severe of severi-
ty of symptoms were scored as 1, 2 or 3, respectively to provide a quantitative
means of data analysis and the total symptom score for every subject each day
was calculated as a sum of multiplied numbers of symptoms experienced by the
numerical severity ratings. A URS was deemed present when (i) total symptom
score was ≥15 on any two consecutive days and (ii) when a subject positively
indicated suffering a common cold on ≥ 3 days according to Jackson et al. (31).
Subjects were also asked to rate the impact of illness symptoms on their ability to
train (above normal, at the same level, below normal or training stopped). The
total number of URS days was also determined as the number of days with a
symptom score of ≥5 according to Predy et al. (44).
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Subjects were also asked to fill in a standard short form of the International Phys-
ical Activity Questionnaire (IPAQ; http://www.ipaq.ki.se/downloads.htm) at
weekly intervals, thus providing a quantitative information on training loads in
metabolic equivalents (MET)-h/week (13). Subjects attended the laboratory every
4 weeks following an overnight fast. Subjects were required to abstain from any
strenuous physical activity for 24 h before coming to the laboratory. During these
visits body mass was recorded and an unstimulated saliva sample was collected.
Venous blood samples were collected only at the start and end of the study period
and the mean values for these haematological values are reported in the Results.
Sample size estimation (21) of 41 subjects per gender group was based on an
expected rate of 2.0 ± 1.0 URS episodes (mean ± SD) during the winter months
(37), a target difference of 30% in number of episodes (effect size 0.6), statistical
power of 80% and a type I error of 5%.
Saliva analysis
The saliva volume collected was estimated by weighing and the saliva flow rate
was calculated. Saliva samples were analysed for secretory immunoglobulin A
(SIgA) using an ELISA kit (Salimetrics, Philadelphia, USA) and α-amylase activ-
ity was measured as previously described (35). Salivary lactoferrin and lysozyme
were analysed using commercially available ELISA kits (Calbiochem, USA and
Biomedical Technologies, USA, respectively). Secretion rates for each of the
salivary AMPs were calculated as the multiple of the saliva flow rate and the
AMP concentration. Values obtained from the 5 visits at 4-week intervals were
averaged for each subject. All saliva assays were carried out in duplicate. Coeffi-
cients of variation (CVs) for the assays were <5% for all salivary AMPs.
Statistical Analysis
The Shapiro-Wilk test was used to determine if data sets were normally distrib-
uted. The difference in proportion of subjects who presented with symptoms of
infection during the trial between the males and females was assessed by a Chi-
squared test. Self-reported training load (h/week), average IPAQ scores (MET-
h/week), anthropometric and haematological variables (including blood leuko-
cyte, neutrophil, monocyte and lymphocyte counts) were compared between
males and females using unpaired t tests for normally distributed data. Changes in
training load over time for both sexes were evaluated by 2-way ANOVA with
post hoc Bonferroni t tests to locate differences from week 1. The salivary AMP
concentrations and secretion rates were compared between males and females
using nonparametric Mann-Whitney tests for data that were not normally distrib-
uted. The changes in the secretion rates of salivary AMPs over the 16 weeks of
the study in males and females were assessed by non-parametric Friedman tests
with post hoc Dunn’s tests to compare values at weeks 4, 8, 12 and 16 with base-
line within sex. Differences between sexes at specific sampling timepoints were
examined using Mann Whitney tests. Statistical significance was accepted at P <
0.05. Data are expressed as mean ± SD or median and interquartile range as
appropriate.
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RESULTS
Anthropometric and haematological variables
There was no significant difference in age between males and females (Table 1)
but males were taller, heavier and had higher BMI than females (all P < 0.01).
Males had higher RBC count, haematocrit and haemoglobin concentration than
females (all P < 0.001). Total blood leukocyte, monocyte and lymphocyte counts
were not different between the sexes but females had higher circulating numbers
of neutrophils than males (P = 0.040).
Training loads
Self-reported weekly training loads (mean ± SD) based on information gathered
in the pre-screening questionnaire were similar in males and females (both 10 ± 3
h/week, P = 0.857).Analysis of the IPAQ questionnaires indicated that the weekly
training loads were relatively stable within both sexes over the 16 weeks of the
study (Figure 1) although there was a significant main effect of time (P<0.001)
with training load falling below week 1 values in weeks 6-11. There was no sig-
nificant effect of sex and no significant sex x time interaction. Training loads
were, on average, about 66 MET-h/week which is equivalent to about 11 h of
moderate-vigorous activity per week. The training loads averaged over the whole
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Table 1. Anthropometric, training and haematological variables in male and female athletes
16-week study period were not sig-
nificantly different between males
and females (Table 1).
Salivary variables
When averaged over the 5 sampling
occasions, saliva flow rates (P <
0.03) and the secretion rates of
lactoferrin, lysozyme and amylase
(Table 2) were significantly higher
in males than females (all P < 0.01).
Concentrations of SIgA and amy-
lase were not different between the
sexes whereas lactoferrin (P =
0.021) and lysozyme (P = 0.033)
concentrations were significantly
higher in males. While there were
significant effects of time (Fried-
man, P < 0.05) for the secretion
rates of lactoferrin, lysozyme, amy-
lase and SIgA in males, there were
significant effects of time only for
amylase and SIgA secretion rates in
females (Figure 2). The changes
over time followed the same pattern
for both sexes.
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Figure 1. Training loads in MET-h/week over the
16-week study period for men (n=147) and
women (n=63) who completed the study. Data
are mean ± SD. There was a main effect of time
(P<0.001) and the location of significant differ-
ences from week 1 are indicated as follows: *
P<0.05, ** P<0.01. There was no significant effect
of sex and no significant sex x time interaction.
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Table 2. Salivary variables in male and female athletes
URS incidence and the severity and duration of URS
Females tended to be more susceptible to URS than males: The proportion of
males and females who experienced one or more URS episodes during the study
period was 40 % of all males and 52 % of all females (P = 0.083, chi-squared test)
and the average number of URS episodes was 0.6 ± 0.8 in males and 0.8 ± 1.0 in
females (P = 0.103). The number of URS days was significantly higher in females
(males: 4.7 ± 5.0 days vs females: 6.8 ± 7.1 days, P = 0.016). When an URS
episode was present, the mean total symptom severity score was not significantly
different between sexes (males: 90 ± 67 vs females: 106 ± 77, P = 0.312) but the
mean duration of symptoms was significantly longer in females (males: 11.6 ±
6.8 days vs females: 15.5 ± 9.3 days, P = 0.024).
Only 17% of subjects reported that they took some medication when suffering
from an URS episode and only 4% reported that they visited their doctor and none
were given prescription drugs. The study results were not corrected for this (i.e.
all URS episodes were included in the analysis).
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Figure 2. Changes in salivary secretion rates over time for (A) Lactoferrin, (B) Lysozyme, (C) Amy-
lase and (D) SIgA. Data are median and interquartile range. Significantly different from baseline
sample within sex: † P<0.05, ‡ P<0.01 (Dunn’s post hoc test applied when Friedman test P<0.05).
Significant difference between males and females at specific timepoint: * P<0.05, ** P<0.01 (Mann
Whitney test).
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DISCUSSION
The main findings of the present study were that although URS incidence was not
significantly different between male and female athletes, the women had more
URS days and their URS episodes lasted several days longer than the men. Sali-
vary SIgA concentration and amylase activity were not significantly affected by
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sex but both lactoferrin and lysozyme concentrations were found to be lower in
the females. Saliva flow rate was ~17% lower in females and the secretion rates
of all the AMPS apart from SIgA were significantly lower in females. In both
sexes saliva AMP secretion rates increased over time which could be due to the
significant fall in the training loads of the athletes that was observed in the middle
part of the study period.
Low SIgA concentration or secretion rate has been identified as a risk factor for
development of URS in physically active individuals (19, 26-28, 37). In the pres-
ent study, we found that female athletes tended to have lower SIgA secretion rates
than male athletes during a 16-week winter training period although this differ-
ence was not statistically significant. It has been suggested that SIgA levels are a
surrogate marker of host protection and the suppression of SIgA after prolonged
exercise or heavy training is itself a probable consequence of altered T lympho-
cyte function (12). Females generally have lower unstimulated saliva flow rates
than males (42), whereas SIgA concentration in unstimulated saliva has been
reported to be unaffected by sex among relatively large cohorts of healthy young
adults (33, 51, 52). A previous smaller scale study reported lower SIgA concen-
tration and secretion rate in females (n=34) than in males (n=46) among a cohort
of student athletes (25). Other small scale studies on elite swimmers have also
reported lower SIgA concentrations in females compared with males (n= 11
females, n = 15 males (26); n = 5 females, n= 7 males (1)), as has a small scale
study of recreational cyclists (n= 8 females, n = 8 males (2)); but, to our knowl-
edge, our investigation is the first large scale study to report a sex difference in
salivary AMP secretion rates in athletes from a range of endurance-based sports.
In the present study, it was observed that the female athletes had lower saliva
amylase secretion rate than male athletes. Amylase, an enzyme that breaks down
starch into maltose, is important to host defence in oral-respiratory mucosal
immunity by inhibiting the adherence and growth of certain bacteria (3). The
lower amylase secretion rate in the saliva of females could be due to lower circu-
lating adrenaline levels that are observed both at rest (54) and after exercise (45)
in females when oestrogen levels are high due to exogenous ovarian hormone
administration. Both increased sympathetic nervous activity (48), and elevated
plasma adrenaline and noradrenaline (11) are known to increase salivary amylase
secretion. In addition, we also found that the secretion rates of lysozyme and
lactoferrin were significantly lower in female athletes than male athletes.
Lysozyme and lactoferrin play important roles in oral-respiratory mucosal immu-
nity against pathogen infection: Lactoferrin possesses the ability to sequester
iron, bind to bacteria, and has antimicrobial activities that act in synergy with
SIgA and lysozyme (15, 34). Therefore, it is possible that the lower secretion
rates of amylase, lysozyme and lactoferrin might leave female athletes at greater
risk of contracting RTIs during winter training periods.
Of course, other factors could also account for differences in infection risk
between the sexes. For example, in the general population, women have been
reported to have fewer blood monocytes and NK cells, but more CD4+ cells and
more neutrophils than men (8, 55) and women appear to suffer from fewer viral
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infections including RTIs than men (6). The present study also found athletic
females to have higher blood neutrophil counts than their male counterparts but it
was the females who appeared to be more susceptible to URS than men. It is pos-
sible that the same training load could have a greater depressive effect on humoral
and systemic immunity (e.g. lower secretion rates of mucosal AMPs and fewer
numbers of circulating B cells and NK cells) for women (25) than for men (that is
not evident in the normal, more sedentary population) but this possibility needs to
be resolved by future research. Such an effect may be responsible for the reversal
of the usual situation of more effective immune function in females into the oppo-
site situation in athletes. Our data support the notion that URS are more prevalent
in female athletes than their male counterparts when they engage in similarly high
training loads. In recent years medical and sport science support personnel have
collected data on rates of injuries and illnesses in large cohorts of athletes attend-
ing (and intending to compete in) large competitive events lasting 2-3 weeks (e.g.
winter and summer Olympic games, athletic and aquatic sport world champi-
onships). The findings from these studies are summarised in Table 3 and suggest
that illness episodes actually are more prevalent in the women than the men (4, 5,
14, 16, 17, 36, 46). About half of the illnesses reported at these events were URS
episodes. Other epidemiological studies on physically active (38) and athletic (30,
32) men and women also suggest that URS are more prevalent in the females.
A limitation of the present study is that the phase of the menstrual cycle (when blood
and saliva samples were taken) was not determined but we did establish that 40% of
the females were taking oral contraceptives. It is possible that the high training loads
of some of the female endurance athletes in our study could have caused them to be
amenorrhoeic and one would expect that this would make their immune variables
more similar to that of men. However, according to the health screen questionnaire
used at the start of the study 96% of the females reported that they had regular peri-
ods so it seems likely that during the study period very few of the females were
amenorrhoeic. This aside, menstrual cycle phase was not found to affect resting sali-
va SIgA responses in endurance trained female athletes (10). Another limitation is
that we did not attempt to distinguish between symptoms of an infectious/illness
nature vs inflammation throughout the 16 weeks of the study design. However, near-
ly all studies to date have used self-reported symptoms rather than pathogen identifi-
cation in studies involving athletes and URS incidence. We used the validated Jack-
son score questionnaire which is a conservative instrument requiring a substantial
symptom score criterion threshold to define a RTI episode (31). Given that the aver-
age duration of URS episodes in our study was 13 days, it is very likely that the vast
majority of episodes were caused by infections as typically inflammation/allergy
symptom episodes generally only last 1-3 days according to Walsh et al. (53).
The major strengths of our study are that we used a validated questionnaire (31)
to determine URS episodes and measured saliva AMPs on 5 occasions at monthly
intervals to better establish the average values for each individual. The average
training loads of the athlete cohort were generally high and were not different
between males and females. Our study population was a group of university ath-
letes on a single campus site so that environment and pathogen exposure were
likely to have been similar for all subjects.
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In conclusion, the findings of this study concur with recent reports of illness inci-
dence at major competitive games indicating that female athletes may be more
susceptible than their male counterparts to URS and that lower oral-respiratory
mucosal immunity (i.e. lower secretion rates of mucosal AMPs), may account for
this in part.
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